Prevention of illness from rhinovirus infection by a topical interferon inducer.
D000287:Administration, Topical; D000914:Antibodies, Viral / Q000032:analysis; D002986:Clinical Trials as Topic; D003139:Common Cold / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D003588:Cytopathogenic Effect, Viral; D003959:Diamines / Q000008:administration & dosage / Q000627:therapeutic use; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007369:Interferon Inducers; D007372:Interferons / Q000032:analysis; D009297:Nasal Mucosa / Q000378:metabolism; D009500:Neutralization Tests; D009666:Nose; D010919:Placebos; D011437:Propylamines / Q000008:administration & dosage* / Q000627:therapeutic use; D012229:Rhinovirus / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity; D013997:Time Factors; D014776:Virus Cultivation
D000914:Antibodies, Viral; D003959:Diamines; D007369:Interferon Inducers; D010919:Placebos; D011437:Propylamines; D000431:Ethanol; D007372:Interferons